S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
US economy grew solid 3.2% in fourth quarter, a slight downgrade from government's initial estimate
Critical asset just had biggest fall on record (Ad)
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Game-Changing Cancer Tech Nears FDA Completion (Ad)
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
US economy grew solid 3.2% in fourth quarter, a slight downgrade from government's initial estimate
Critical asset just had biggest fall on record (Ad)
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Game-Changing Cancer Tech Nears FDA Completion (Ad)
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
US economy grew solid 3.2% in fourth quarter, a slight downgrade from government's initial estimate
Critical asset just had biggest fall on record (Ad)
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Game-Changing Cancer Tech Nears FDA Completion (Ad)
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants
S&P 500   5,069.76
DOW   38,949.02
QQQ   435.27
FedEx ends naming rights agreement for the Washington Commanders stadium long known as FedEx Field
Critical asset just had biggest fall on record (Ad)
Are NFTs Back? Why NFTs Will Make a Comeback in 2024
US economy grew solid 3.2% in fourth quarter, a slight downgrade from government's initial estimate
Critical asset just had biggest fall on record (Ad)
Dubai's sky-high aspirations find a new outlet as it hosts a jet suit race for 'Iron Man' pilots
Apple Cancels Its 10-Year Electric Car Project, Moves Some Employees to AI Division
Game-Changing Cancer Tech Nears FDA Completion (Ad)
Leaders, Here Are 4 Ways You're Inadvertently Destroying Trust in the Workplace (and What to Do Instead)
Wendy's says it has no plans to raise prices during the busiest times at its restaurants

Synlogic (SYBX) Competitors

$1.87
-0.02 (-1.06%)
(As of 02/28/2024 ET)

SYBX vs. PIRS, MBRX, EDSA, FBIO, MIRA, LABP, PPBT, RDHL, NCNA, and TFFP

Should you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Pieris Pharmaceuticals (PIRS), Moleculin Biotech (MBRX), Edesa Biotech (EDSA), Fortress Biotech (FBIO), MIRA Pharmaceuticals (MIRA), Landos Biopharma (LABP), Purple Biotech (PPBT), RedHill Biopharma (RDHL), NuCana (NCNA), and TFF Pharmaceuticals (TFFP). These companies are all part of the "pharmaceutical preparations" industry.

Synlogic vs.

Synlogic (NASDAQ:SYBX) and Pieris Pharmaceuticals (NASDAQ:PIRS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, community ranking, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Pieris Pharmaceuticals has a net margin of -59.25% compared to Synlogic's net margin of -8,396.04%. Synlogic's return on equity of -95.30% beat Pieris Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Synlogic-8,396.04% -95.30% -67.97%
Pieris Pharmaceuticals -59.25%-98.12%-34.57%

Synlogic received 53 more outperform votes than Pieris Pharmaceuticals when rated by MarketBeat users. Likewise, 69.68% of users gave Synlogic an outperform vote while only 62.90% of users gave Pieris Pharmaceuticals an outperform vote.

CompanyUnderperformOutperform
SynlogicOutperform Votes
331
69.68%
Underperform Votes
144
30.32%
Pieris PharmaceuticalsOutperform Votes
278
62.90%
Underperform Votes
164
37.10%

47.2% of Synlogic shares are held by institutional investors. Comparatively, 75.0% of Pieris Pharmaceuticals shares are held by institutional investors. 8.0% of Synlogic shares are held by company insiders. Comparatively, 8.9% of Pieris Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Pieris Pharmaceuticals has higher revenue and earnings than Synlogic. Pieris Pharmaceuticals is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Synlogic$1.18M14.56-$66.15M-$12.76-0.15
Pieris Pharmaceuticals$25.90M0.65-$33.28M-$0.35-0.49

In the previous week, Pieris Pharmaceuticals had 1 more articles in the media than Synlogic. MarketBeat recorded 3 mentions for Pieris Pharmaceuticals and 2 mentions for Synlogic. Pieris Pharmaceuticals' average media sentiment score of 0.96 beat Synlogic's score of 0.85 indicating that Pieris Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Synlogic
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Pieris Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Synlogic currently has a consensus price target of $65.00, suggesting a potential upside of 3,375.94%. Given Synlogic's higher probable upside, equities research analysts clearly believe Synlogic is more favorable than Pieris Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Synlogic
1 Sell rating(s)
3 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00
Pieris Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

Synlogic has a beta of 1.21, suggesting that its stock price is 21% more volatile than the S&P 500. Comparatively, Pieris Pharmaceuticals has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Summary

Pieris Pharmaceuticals beats Synlogic on 9 of the 17 factors compared between the two stocks.


Get Synlogic News Delivered to You Automatically

Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

SYBX vs. The Competition

MetricSynlogicPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$17.37M$6.31B$5.02B$7.52B
Dividend YieldN/A2.79%2.87%3.87%
P/E Ratio-0.156.90191.7713.45
Price / Sales14.56164.442,908.5171.07
Price / CashN/A19.4294.2954.63
Price / Book0.114.734.454.63
Net Income-$66.15M$148.06M$112.60M$211.02M
7 Day Performance-4.10%6.02%4.72%2.28%
1 Month Performance-44.01%11.17%9.87%3.39%
1 Year Performance-82.19%5.67%12.46%7.45%

Synlogic Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PIRS
Pieris Pharmaceuticals
2.9743 of 5 stars
$0.17
+6.3%
N/A-88.7%$16.72M$25.90M-0.48127Short Interest ↓
MBRX
Moleculin Biotech
3.6343 of 5 stars
$0.50
flat
$8.00
+1,500.3%
-50.2%$16.70MN/A-0.5515
EDSA
Edesa Biotech
3.5968 of 5 stars
$5.36
-0.2%
$39.00
+627.6%
-49.6%$16.99MN/A0.0016Short Interest ↓
FBIO
Fortress Biotech
2.4456 of 5 stars
$1.78
-4.3%
$55.00
+2,989.9%
-80.6%$15.91M$75.74M-0.15187Short Interest ↑
MIRA
MIRA Pharmaceuticals
0.3349 of 5 stars
$1.07
+2.9%
N/AN/A$15.82MN/A0.002Short Interest ↑
Gap Down
LABP
Landos Biopharma
0 of 5 stars
$5.73
+2.3%
N/A+67.4%$17.86M$18M-1.5222Positive News
High Trading Volume
PPBT
Purple Biotech
2.9599 of 5 stars
$0.72
-5.3%
$9.00
+1,157.9%
-64.8%$15.76MN/A-0.6720Analyst Report
RDHL
RedHill Biopharma
0 of 5 stars
$0.53
-3.6%
N/A-94.0%$15.72M$61.80M0.00113Short Interest ↓
News Coverage
Positive News
Gap Up
NCNA
NuCana
3.4755 of 5 stars
$0.34
-2.8%
$5.00
+1,357.7%
-74.7%$17.94MN/A-0.4228Short Interest ↓
Gap Up
TFFP
TFF Pharmaceuticals
2.5451 of 5 stars
$6.54
-5.8%
$137.50
+2,002.4%
-67.2%$15.50M$500,000.000.0015Upcoming Earnings
Positive News
Gap Up

Related Companies and Tools

This page (NASDAQ:SYBX) was last updated on 2/29/2024 by MarketBeat.com Staff